PT2199390T - Anticorpo anti-epha2 - Google Patents
Anticorpo anti-epha2Info
- Publication number
- PT2199390T PT2199390T PT88284823T PT08828482T PT2199390T PT 2199390 T PT2199390 T PT 2199390T PT 88284823 T PT88284823 T PT 88284823T PT 08828482 T PT08828482 T PT 08828482T PT 2199390 T PT2199390 T PT 2199390T
- Authority
- PT
- Portugal
- Prior art keywords
- epha2 antibody
- epha2
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007224007 | 2007-08-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2199390T true PT2199390T (pt) | 2017-03-15 |
Family
ID=40387351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT88284823T PT2199390T (pt) | 2007-08-30 | 2008-08-29 | Anticorpo anti-epha2 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US8449882B2 (pt) |
| EP (1) | EP2199390B1 (pt) |
| JP (2) | JP5312333B2 (pt) |
| KR (4) | KR101561416B1 (pt) |
| CN (1) | CN101848998B (pt) |
| AU (1) | AU2008292352B2 (pt) |
| BR (1) | BRPI0816094A2 (pt) |
| CA (1) | CA2698146C (pt) |
| CO (1) | CO6180469A2 (pt) |
| CY (1) | CY1118763T1 (pt) |
| DK (1) | DK2199390T3 (pt) |
| ES (1) | ES2618316T3 (pt) |
| HR (1) | HRP20170407T1 (pt) |
| HU (1) | HUE032301T2 (pt) |
| IL (1) | IL204211A (pt) |
| LT (1) | LT2199390T (pt) |
| MX (1) | MX2010002248A (pt) |
| MY (1) | MY150621A (pt) |
| NZ (1) | NZ583966A (pt) |
| PL (1) | PL2199390T3 (pt) |
| PT (1) | PT2199390T (pt) |
| RU (1) | RU2525133C2 (pt) |
| SI (1) | SI2199390T1 (pt) |
| TW (1) | TWI443109B (pt) |
| WO (1) | WO2009028639A1 (pt) |
| ZA (1) | ZA201001340B (pt) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8518405B2 (en) | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
| WO2012008397A1 (ja) * | 2010-07-12 | 2012-01-19 | 第一三共株式会社 | 抗ｅｐｈａ２抗体及びその用途 |
| KR20130048242A (ko) | 2010-07-22 | 2013-05-09 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 항-종양 항원 항체 및 이용 방법 |
| EP2446895A1 (en) * | 2010-10-01 | 2012-05-02 | Stemgen S.P.A. | EPH receptor expression in tumor stem cells |
| US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
| US9402916B2 (en) | 2011-03-17 | 2016-08-02 | The University Of Birmingham | Re-directed immunotherapy |
| JP5875054B2 (ja) | 2013-02-13 | 2016-03-02 | 国立大学法人 東京大学 | がんの検査方法及び検査用キット |
| US11554181B2 (en) | 2014-09-05 | 2023-01-17 | The University Of North Carolina At Charlotte | Tumor specific antibody conjugates and uses therefor |
| WO2017180530A1 (en) * | 2016-04-14 | 2017-10-19 | Academia Sinica | Inhibition of scube2, a novel vegfr2 co-receptor, suppresses tumor angiogenesis |
| EP3468587A4 (en) * | 2016-06-09 | 2020-02-19 | University of Leicester | MONOCLONAL ANTIBODIES, COMPOSITIONS AND METHOD FOR DETECTING MUCIN-LIKE PROTEIN (MLP) AS A BIOMARKER FOR OVARIAL AND PANCREASER |
| CN110198956A (zh) * | 2017-01-23 | 2019-09-03 | 学校法人东洋大学 | 抗epha2抗体和使用该抗epha2抗体的epha2免疫检测 |
| US11421032B2 (en) * | 2017-05-22 | 2022-08-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for inhibition of MICA/B shedding |
| CN109879965B (zh) * | 2017-12-06 | 2022-11-11 | 北京科立思维生物科技有限公司 | 抗epha2单链抗体、抗cd3e单链抗体及融合蛋白及其应用 |
| KR20230122685A (ko) | 2018-09-06 | 2023-08-22 | 다이이찌 산쿄 가부시키가이샤 | 신규 고리형 디뉴클레오티드 유도체 및 그 항체 약물콘쥬게이트 |
| CA3120800A1 (en) | 2018-12-17 | 2020-06-25 | Revitope Limited | Twin immune cell engager |
| TW202241454A (zh) | 2021-02-01 | 2022-11-01 | 日商第一三共股份有限公司 | 抗體－免疫賦活化劑共軛物之新穎製造方法 |
| EP4301785A1 (en) * | 2021-03-05 | 2024-01-10 | Atreca, Inc. | Epha2 antibodies |
| KR20230157983A (ko) | 2021-03-12 | 2023-11-17 | 다이이찌 산쿄 가부시키가이샤 | 당사슬 및 당사슬을 포함하는 의약품의 제조 방법 |
| CN117693519A (zh) | 2021-05-25 | 2024-03-12 | 瓦克斯细胞生物 | 基于单体拟抗体的嵌合抗原受体和包含其的免疫细胞 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE185601T1 (de) | 1990-07-10 | 1999-10-15 | Cambridge Antibody Tech | Verfahren zur herstellung von spezifischen bindungspaargliedern |
| ATE181571T1 (de) | 1991-09-23 | 1999-07-15 | Medical Res Council | Methoden zur herstellung humanisierter antikörper |
| PT1696031E (pt) | 1991-12-02 | 2010-06-25 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| DE69333823T2 (de) | 1992-03-24 | 2006-05-04 | Cambridge Antibody Technology Ltd., Melbourn | Verfahren zur herstellung von gliedern von spezifischen bindungspaaren |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| CA2177367A1 (en) | 1993-12-03 | 1995-06-08 | Andrew David Griffiths | Recombinant binding proteins and peptides |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| ATE219517T1 (de) | 1995-08-18 | 2002-07-15 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
| US6972323B1 (en) | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
| DK1144607T5 (da) | 1999-07-20 | 2009-10-05 | Morphosys Ag | Fremgangsmåde til præsentation af (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger |
| JP4948728B2 (ja) | 1999-08-17 | 2012-06-06 | パーデュー・リサーチ・ファウンデーション | 癌診断用抗体 |
| ATE324877T1 (de) | 1999-08-17 | 2006-06-15 | Purdue Research Foundation | Behandlung von metastatischer krankheit |
| CZ304942B6 (cs) | 2000-03-31 | 2015-02-04 | Purdue Research Foundation | Léčivo pro zvyšování specifické eliminace populace tumorových buněk a farmaceutický prostředek obsahující konjugát fosfát-FITC nebo fosfát-dinitrofenyl |
| US20020025536A1 (en) | 2000-06-26 | 2002-02-28 | Jeno Gyuris | Methods and reagents for isolating biologically active antibodies |
| US7101976B1 (en) | 2000-09-12 | 2006-09-05 | Purdue Research Foundation | EphA2 monoclonal antibodies and methods of making and using same |
| EP3263702A1 (en) | 2000-10-06 | 2018-01-03 | Kyowa Hakko Kirin Co., Ltd. | Cells producing antibody compositions |
| KR20030066590A (ko) | 2001-06-05 | 2003-08-09 | 발레오 | 변속 장치 |
| ATE440869T1 (de) | 2001-06-20 | 2009-09-15 | Fibron Ltd | Fgfr3 blockierende antikírper, verfahren zum screening darauf und verwendungen davon |
| US20040247592A1 (en) | 2001-07-03 | 2004-12-09 | Roifman Chaim M. | Ephrin and eph receptor mediated immune modulation |
| FR2838742B1 (fr) | 2002-04-23 | 2004-07-09 | Inst Nat Sante Rech Med | Epitopes t de l'antigene epha2 |
| AU2004293034B2 (en) * | 2002-05-10 | 2012-02-02 | Medimmune, Llc | EphA2 agonistic monoclonal antibodies and methods of use thereof |
| US20040091486A1 (en) | 2002-05-10 | 2004-05-13 | Kinch Michael S. | EphA2 agonistic monoclonal antibodies and methods of use thereof |
| CA2485373A1 (en) * | 2002-05-10 | 2003-11-20 | Medimmune, Inc. | Epha2 monoclonal antibodies and methods of use thereof |
| US20050152899A1 (en) | 2002-05-10 | 2005-07-14 | Kinch Michael S. | EphA2 agonistic monoclonal antibodies and methods of use thereof |
| WO2003099313A1 (en) | 2002-05-23 | 2003-12-04 | Purdue Research Foundation | Low molecular weight protein tyrosine phosphatase (lmw-ptp) as a diagnostic and therapeutic target |
| US7326552B1 (en) | 2002-06-21 | 2008-02-05 | Takeda San Diego, Inc. | Wild-type kinase domain of human Ephrin receptor A2 (EPHA2) and crystallization thereof |
| EP1852441B1 (en) | 2002-09-24 | 2012-03-28 | The Burnham Institute | Agents that modulate EPH receptor activity |
| AU2003268345A1 (en) | 2002-09-24 | 2004-04-19 | The Burnham Institute | Novel agents that modulate eph receptor activity |
| PT1583830E (pt) | 2003-01-07 | 2006-11-30 | Symphogen As | Método para produzir proteínas policlonais recombinantes |
| AU2003900541A0 (en) | 2003-02-07 | 2003-02-20 | Ludwig Institute For Cancer Research | Modulation of cell adhesion and tumour cell metastasis |
| EP1618184A4 (en) | 2003-04-11 | 2006-06-21 | Medimmune Inc | EPHA2, HYPOPROLIFERATIVE CELL DISORDERS, AND EPITHELIAL AND ENDOTHELIAL RECONSTITUTION |
| JP4764818B2 (ja) | 2003-04-11 | 2011-09-07 | メディミューン，エルエルシー | 組換えｉｌ−９抗体およびその使用 |
| EP1617864A4 (en) | 2003-04-11 | 2006-06-21 | Medimmune Inc | EPHA2 AND NON-NEOPLASTIC HYPERPROLIFERATIVE CELL TROUBLESHOOTING |
| JP4838720B2 (ja) | 2003-05-13 | 2011-12-14 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 転移および転移がもたらす骨格関連現象を調節する方法 |
| US20050147593A1 (en) | 2003-05-22 | 2005-07-07 | Medimmune, Inc. | EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders |
| AU2004242845B2 (en) | 2003-05-31 | 2011-06-02 | Amgen Research (Munich) Gmbh | Human-anti-human CD3 binding molecules |
| US20050009033A1 (en) | 2003-07-08 | 2005-01-13 | The Regents Of The University Of California | Breast cancer genes |
| WO2005016381A2 (en) | 2003-07-21 | 2005-02-24 | Medimmune, Inc. | Combination therapy for the treatment and prevention of cancer using epha2, pcdgf, and haah |
| CA2533789C (en) | 2003-07-30 | 2013-09-17 | University Of Pittsburgh Of The Commnonwealth System Of Higher Education | Epha2 t-cell epitope agonists and uses therefor |
| EP2272566A3 (en) | 2003-08-18 | 2013-01-02 | MedImmune, LLC | Humanisation of antibodies |
| AU2004280333A1 (en) | 2003-08-22 | 2005-04-21 | Medimmune, Llc | Humanization of antibodies |
| KR20060130038A (ko) | 2003-10-15 | 2006-12-18 | 메디뮨 인코포레이티드 | 리스테리아에 의거한 ＥｐｈＡ２ 백신 |
| DE10354115A1 (de) | 2003-11-19 | 2005-07-21 | Beiersdorf Ag | Neue Verwendung von Tensidsystemen zur Verringerung der Schädigung hauteigener Enzyme |
| WO2005056766A2 (en) | 2003-12-04 | 2005-06-23 | Medimmune, Inc. | TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES |
| WO2005067460A2 (en) | 2003-12-24 | 2005-07-28 | Medimmune, Inc. | Epha2 vaccines |
| US20060286102A1 (en) | 2004-05-14 | 2006-12-21 | Pei Jin | Cell surface receptor isoforms and methods of identifying and using the same |
| WO2006023403A2 (en) | 2004-08-16 | 2006-03-02 | Medimmune, Inc. | Eph receptor fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity |
| US8222253B2 (en) | 2004-10-23 | 2012-07-17 | Case Western Reserve University | Peptide and small molecule agonists of EphA and their uses |
| CA2585717A1 (en) | 2004-10-27 | 2006-05-04 | Medimmune Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
| US20060121043A1 (en) | 2004-10-27 | 2006-06-08 | Medimmune, Inc. | Use of modulators of EphA2 and EphrinA1 for the treatment and prevention of infections |
| JP2008518022A (ja) | 2004-10-27 | 2008-05-29 | メディミューン，インコーポレーテッド | 線維症関連疾患を治療するためのＥｐｈＡ２およびエフリンＡ１モジュレーター |
| CA2597198C (en) | 2005-02-04 | 2016-06-21 | Raven Biotechnologies, Inc. | Antibodies that bind to epha2 and methods of use thereof |
| US20090030187A1 (en) | 2005-03-14 | 2009-01-29 | Tous Guillermo I | Macromolecules comprising a thioether cross-link |
| MX2007014598A (es) | 2005-05-20 | 2008-02-07 | Univ Illinois | Composiciones y metodos para tratar condiciones relacionadas con senalizacion de efrina con cupredoxinas. |
| AU2006287416A1 (en) * | 2005-09-07 | 2007-03-15 | Medimmune, Llc | Toxin conjugated Eph receptor antibodies |
| US8236772B2 (en) | 2005-09-16 | 2012-08-07 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of modulating angiogenesis and screening compounds for activity in modulating angiogenesis |
| EP1968998A4 (en) * | 2005-12-21 | 2010-01-27 | Medimmune Llc | AFFINITY-OPTIMIZED EPHA2-AGONISTIC ANTIBODIES AND METHODS FOR THEIR USE |
| EP1981532A4 (en) | 2005-12-21 | 2010-06-30 | Medimmune Llc | EPHA2 MOLECULES AND USES THEREOF |
| US20070212337A1 (en) | 2006-02-01 | 2007-09-13 | The Johns Hopkins University | Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders |
| US20080003210A1 (en) | 2006-03-13 | 2008-01-03 | Medimmune, Inc. | Non-human primate receptor tyrosine kinases |
| CA3149553C (en) | 2006-06-12 | 2023-11-21 | Aptevo Research And Development Llc | Single-chain multivalent binding proteins with effector function |
| AU2007274738B2 (en) | 2006-07-18 | 2013-11-28 | Sanofi-Aventis | Antagonist antibody against EphA2 for the treatment of cancer |
| US20110008347A1 (en) | 2006-12-01 | 2011-01-13 | Agency For Science ,Technology And Research | Cancer-related protein kinases |
| US20100166746A1 (en) | 2006-12-04 | 2010-07-01 | Medlmmune Way | High potency recombinant antibodies, methods for producing them and use in cancer therapy |
| US20100093626A1 (en) | 2006-12-15 | 2010-04-15 | Bingcheng Wang | Peptide and small molecule agonists of epha and their uses in disease |
| US20080199426A1 (en) | 2007-01-11 | 2008-08-21 | Sukhatme Vikas P | Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders |
| CA2683864A1 (en) | 2007-04-13 | 2008-10-23 | Cytopathfinder, Inc. | Compound profiling method |
| KR20100056438A (ko) | 2007-06-18 | 2010-05-27 | 메디뮨 엘엘씨 | ＥｐｈＡ2 및 ＥｒｂＢ2를 발현하는 세포의 상승적 치료 방법 |
| CA2698419C (en) | 2007-09-07 | 2019-11-12 | Edward Dolk | Binding molecules with multiple binding sites, compositions comprising the same and uses thereof |
| WO2009052830A1 (en) | 2007-10-22 | 2009-04-30 | Genmab A/S | Novel antibody therapies |
-
2008
- 2008-08-29 WO PCT/JP2008/065486 patent/WO2009028639A1/ja active Application Filing
- 2008-08-29 KR KR1020157008277A patent/KR101561416B1/ko not_active IP Right Cessation
- 2008-08-29 DK DK08828482.3T patent/DK2199390T3/en active
- 2008-08-29 MX MX2010002248A patent/MX2010002248A/es active IP Right Grant
- 2008-08-29 TW TW97133095A patent/TWI443109B/zh not_active IP Right Cessation
- 2008-08-29 PT PT88284823T patent/PT2199390T/pt unknown
- 2008-08-29 ES ES08828482.3T patent/ES2618316T3/es active Active
- 2008-08-29 HU HUE08828482A patent/HUE032301T2/en unknown
- 2008-08-29 SI SI200831748A patent/SI2199390T1/sl unknown
- 2008-08-29 RU RU2010111896/10A patent/RU2525133C2/ru not_active IP Right Cessation
- 2008-08-29 JP JP2009530190A patent/JP5312333B2/ja not_active Expired - Fee Related
- 2008-08-29 LT LTEP08828482.3T patent/LT2199390T/lt unknown
- 2008-08-29 KR KR1020157008278A patent/KR101561417B1/ko not_active IP Right Cessation
- 2008-08-29 KR KR1020147036821A patent/KR101561403B1/ko not_active IP Right Cessation
- 2008-08-29 CN CN200880114621.5A patent/CN101848998B/zh not_active Expired - Fee Related
- 2008-08-29 AU AU2008292352A patent/AU2008292352B2/en not_active Ceased
- 2008-08-29 PL PL08828482T patent/PL2199390T3/pl unknown
- 2008-08-29 MY MYPI20100815 patent/MY150621A/en unknown
- 2008-08-29 KR KR1020107004260A patent/KR101521668B1/ko not_active IP Right Cessation
- 2008-08-29 EP EP08828482.3A patent/EP2199390B1/en not_active Not-in-force
- 2008-08-29 NZ NZ583966A patent/NZ583966A/en not_active IP Right Cessation
- 2008-08-29 CA CA2698146A patent/CA2698146C/en not_active Expired - Fee Related
- 2008-08-29 BR BRPI0816094 patent/BRPI0816094A2/pt not_active Application Discontinuation
-
2010
- 2010-02-24 ZA ZA2010/01340A patent/ZA201001340B/en unknown
- 2010-02-25 US US12/713,041 patent/US8449882B2/en active Active
- 2010-02-28 IL IL204211A patent/IL204211A/en not_active IP Right Cessation
- 2010-03-11 CO CO10028981A patent/CO6180469A2/es active IP Right Grant
-
2013
- 2013-05-22 US US13/899,996 patent/US9150657B2/en not_active Expired - Fee Related
- 2013-06-05 JP JP2013118547A patent/JP5688433B2/ja not_active Expired - Fee Related
-
2015
- 2015-10-05 US US14/875,360 patent/US20160031987A1/en not_active Abandoned
-
2017
- 2017-03-13 HR HRP20170407TT patent/HRP20170407T1/hr unknown
- 2017-03-16 CY CY20171100336T patent/CY1118763T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201001340B (en) | Anti-epha2 antibody | |
| HK1136970A1 (en) | Penta-specific antibody | |
| EP2138576A4 (en) | ANTI-CLAUDIN-4 ANTIBODY | |
| GB0708002D0 (en) | Antibodies | |
| EP2241578A4 (en) | ANTI-CLDN6 ANTIBODIES | |
| IL229512A0 (en) | Anti-vegf antibodies | |
| ZA201102119B (en) | Improved antibody libraies | |
| EP2172483A4 (en) | ANTI-MUC17 ANTIBODY | |
| HK1146728A1 (en) | Modified antibody constant region | |
| SI2200700T1 (sl) | Nova protitelesa | |
| IL204835A0 (en) | Humanized antibody | |
| GB0821100D0 (en) | Antibodies | |
| GB0615662D0 (en) | Antibody | |
| IL205073A0 (en) | Anti-bst2 antibody | |
| EP2337798A4 (en) | BSA-SPECIFIC ANTIBODIES | |
| GB0718737D0 (en) | Antibodies | |
| GB0702888D0 (en) | Novel Antibodies | |
| ZA201006099B (en) | Anti-tyrp1 antibodies | |
| ZA201007976B (en) | Anti-pirb antibodies | |
| GB0818356D0 (en) | Antibodies | |
| GB0911770D0 (en) | Antibody | |
| GB0724185D0 (en) | Antibodies | |
| GB0817622D0 (en) | Antibody | |
| GB0817621D0 (en) | Antibody | |
| GB0706965D0 (en) | Humanized antibody |